Susquehanna Fundamental Investments, LLC Allovir, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.13 - $8.79 $77,553 - $165,058	-18,778 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$6.75 - $13.52 $27,270 - $54,620	-4,040 Reduced 17.71%	18,778 $127,000
Q4 2021 Feb 14, 2022	SELL	$12.94 - $25.99 $12,940 - $25,990	-1,000 Reduced 4.2%	22,818 $295,000
Q3 2021 Nov 15, 2021	BUY	$16.97 - $25.06 $404,191 - $596,879	23,818 New	23,818 $597,000
Q1 2021 May 17, 2021	SELL	$20.81 - $45.5 $486,246 - $1.06 Million	-23,366 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$23.94 - $46.81 $119,771 - $234,190	-5,003 Reduced 17.64%	23,366 $898,000
Q3 2020 Nov 16, 2020	BUY	$21.05 - $42.7 $597,167 - $1.21 Million	28,369 New	28,369 $780,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $54M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.